{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:06Z","timestamp":1789092426201,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the adequacy of levothyroxine therapy, assessed by serum thyrotropin (TSH) levels, in patients with low-risk differentiated thyroid carcinoma (DTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, retrospective cohort study including patients with low-risk DTC. Dynamic risk stratification was performed 12 months after initial treatment and at the last follow-up visit according to the 2015 American Thyroid Association (ATA) guidelines. Patients were categorized based on treatment response as excellent, indeterminate, biochemical incomplete, and structural incomplete. Levothyroxine adequacy was determined according to ATA-recommended TSH target values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1016 patients (median age, 48 years; 80.7% women; 91.4% papillary thyroid carcinoma) were followed for a median of 6.6 years. Total thyroidectomy was performed in 935 (92.0%) (plus radioiodine in 667), while 81 (8.0%) underwent lobectomy. An excellent response was observed in 633 (62.3%) at 12 months and in 761 (77.8%) at the last follow-up. Treatment adequacy increased from 264 (26.0%) at 12 months to 387 (39.5%) at the final visit (P&amp;lt;0.001). Among patients with excellent response, treatment adequacy rose from 25.8% to 44.3% (P&amp;lt;0.001). At the last visit, inadequacy was primarily due to excessive levothyroxine in patients with excellent response (30.5%), and insufficient dosing in those with indeterminate or biochemical incomplete response (62.2% and 50.0%, respectively). Levothyroxine dose instability correlated significantly with treatment inadequacy (P&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The low rate of treatment adequacy highlights the need of personalized levothyroxine dosing to optimize therapeutic outcomes and minimize the risks of under- or overdosing in patients with low-risk DTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1652862","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:14:55Z","timestamp":1765516495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of levothyroxine therapy adequacy in low-risk differentiated thyroid carcinoma: a multicenter cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan J.","family":"D\u00edez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Anda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alcazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Galofr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Familiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Pamplona-Civera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Herrero-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda R.","family":"Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"S\u00e1nchez-Ragnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rodriguez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Orois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"S\u00e1nchez-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.18528","article-title":"Changes in trends in thyroid cancer incidence in the United States, 1992 to 2016","volume":"322","author":"Powers","year":"2019","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00598-y","article-title":"Pathogenesis of cancers derived from thyroid follicular cells","volume":"23","author":"Fagin","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12020-024-04155-x","article-title":"Nongenetic risk factors for thyroid cancer: an umbrella review of evidence","volume":"88","author":"Peng","year":"2025","journal-title":"Endocrine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad118","article-title":"Mechanistic insights of thyroid cancer progression","volume":"164","author":"Leandro-Garc\u00eda","year":"2023","journal-title":"Endocrinology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0294","article-title":"An update on the management of low-risk differentiated thyroid cancer","volume":"26","author":"Lamartina","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00448-z","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"Schlumberger","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0449","article-title":"All-cause and cause-specific mortality among low-risk differentiated thyroid cancer survivors in the United States","volume":"34","author":"Tran","year":"2024","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0085","article-title":"Lobectomy in patients with differentiated thyroid cancer: indications and follow-up","volume":"26","author":"Park","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-25-0287","article-title":"Active surveillance for small papillary thyroid carcinoma","volume":"32","author":"Ito","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.10.008","article-title":"Thyroid hormone suppression therapy","volume":"48","author":"Biondi","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19052","article-title":"Hyperthyroidism: A review","volume":"330","author":"Lee","year":"2023","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0178","article-title":"Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0232","article-title":"In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response","volume":"21","author":"Vaisman","year":"2011","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03548-8","article-title":"Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy","volume":"83","author":"Gigliotti","year":"2024","journal-title":"Endocrine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0033","article-title":"Thyrotropin suppression for papillary thyroid cancer: A physician survey study","volume":"31","author":"Papaleontiou","year":"2021","journal-title":"Thyroid"},{"key":"B19","article-title":"Thyroid differentiated and anaplastic carcinoma","volume-title":"AJCC Cancer Staging Manual. 8th ed","author":"Tuttle","year":"2017"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4290","article-title":"Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine","volume":"101","author":"Momesso","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04342.x","article-title":"Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy","volume":"77","author":"Vaisman","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2015.02.006","article-title":"Clinical guideline for management of patients with low risk differentiated thyroid carcinoma","volume":"62","author":"D\u00edez","year":"2015","journal-title":"Endocrinol Nutr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2022.11.031","article-title":"Evolution of suppressing TSH therapy at diagnosis and in the long-term follow-up in a cohort of differentiated thyroid cancer","volume":"69","author":"D\u00edaz-Soto","year":"2022","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e38290","DOI":"10.1097\/MD.0000000000038290","article-title":"Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: A real-world experience at an endocrine center in Bangkok","volume":"103","author":"Thewjitcharoen","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14787","article-title":"Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients","volume":"97","author":"Yavuz","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12902-021-00871-x","article-title":"A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study)","volume":"21","author":"Ming","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.2686","article-title":"Levothyroxine use in the United States, 2008-2018","volume":"181","author":"Brito","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01074-x","article-title":"Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments","volume":"42","author":"Grani","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15111","article-title":"Tracking dynamic evolution of low- and intermediate-risk differentiated thyroid cancer: Identification of individuals at risk of recurrence","volume":"101","author":"Volpi","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01411","article-title":"Role of patient maximizing-minimizing preferences in thyroid cancer surveillance","volume":"37","author":"Evron","year":"2019","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0287","article-title":"Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma","volume":"25","author":"Wang","year":"2015","journal-title":"Thyroid"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0330","article-title":"Association between serum thyrotropin and cancer recurrence in differentiated thyroid cancer: A population-based retrospective cohort study","volume":"35","author":"Qiang","year":"2025","journal-title":"Thyroid"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2017-0159","article-title":"An Italian survey of compliance with major guidelines for L-thyroxine of primary hypothyroidism","volume":"24","author":"Vezzani","year":"2018","journal-title":"Endocr Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00699","article-title":"Adherence to levothyroxine treatment among patients with hypothyroidism: A Northeastern Italian survey","volume":"9","author":"Cappelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2019.1619730","article-title":"Are illness perceptions, beliefs about medicines and Type D personality associated with medication adherence among thyroid cancer survivors? A study from the population-based PROFILES registry","volume":"35","author":"Mols","year":"2020","journal-title":"Psychol Health"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0414","article-title":"Impact of a forced dose-equivalent levothyroxine brand switch on plasma thyrotropin: A cohort study","volume":"30","author":"Flinterman","year":"2020","journal-title":"Thyroid"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2378984","article-title":"Importance of right communication with healthcare providers and patients about the new levothyroxine formulation: an expert opinion from Asia Pacific Thyroid Advisory Board","volume":"40","author":"Razvi","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa297","article-title":"Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with radioiodine","volume":"105","author":"Matrone","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000457793","article-title":"Nodular thyroid disease and thyroid cancer in the era of precision medicine","volume":"6","author":"Zafon","year":"2017","journal-title":"Eur Thyroid J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003074","article-title":"Is less more? A microsimulation model comparing cost-effectiveness of the revised American thyroid association\u2019s 2015 to 2009 guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer","volume":"271","author":"White","year":"2020","journal-title":"Ann Surg"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8:38","DOI":"10.1186\/1472-6947-8-38","article-title":"Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review","author":"Francke","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"key":"B44","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1652862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:14:56Z","timestamp":1765516496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1652862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":44,"alternative-id":["10.3389\/fendo.2025.1652862"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1652862","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1652862"}}